Gut Health
Anti-TL1A Therapy SPY002 Hits Primary Endpoint in UC Induction Trial
Gut-inflammation targeting moves further into clinical validation — with implications for next-gen functional ingredien…
Gut Health 5 stories
Gut Health
Fight CRC Expands Climb for a Cure Nationwide on July 18
The expanded virtual format broadens reach for a cause increasingly linked to diet, fiber intake, and gut-health resear…
Gut Health
FDA Accepts BLA for Vedolizumab Biosimilar AVT16 from Alvotech
The gut-health biologics pipeline inches forward as a vedolizumab biosimilar clears a key regulatory milestone — with i…
Gut Health
FDA Accepts BLA for AVT16, Vedolizumab Biosimilar Targeting IBD
The gut-targeted integrin inhibitor category draws biosimilar competition as regulators advance interchangeability revi…
Gut Health
FDA Accepts BLA for AVT16, Proposed Vedolizumab Biosimilar
The BLA acceptance marks a regulatory milestone for the gut-inflammation biologics pipeline, with biosimilar competitio…